Nonetheless, the present results prove that the TLR4–NF-κB–MyD88 pathway can be activated by anti-TB drugs, indicating that pathway activation plays an essential role in the gut–liver axis associated with ATDILI development. Here, NFKB1 is linked to tuberculosis.